m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03076
 [1]
Histone modification HNRNPA2B1 JMJD6 Downstream Gene Direct Enhancement m6A modification STING1 STING1 hnRNPA2B1 : m6A sites
m6A Modification:
m6A Regulator Heterogeneous nuclear ribonucleoproteins A2/B1 (HNRNPA2B1) READER
 Regulator Info 
m6A Target Stimulator of interferon genes protein (STING1)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Bifunctional arginine demethylase and lysyl-hydroxylase JMJD6 (JMJD6) ERASER View Details
Regulated Target Heterogeneous nuclear ribonucleoprotein A2/B1 (HNRNPA2B1) View Details
Crosstalk Relationship Histone modification  →  m6A Enhancement
Crosstalk Mechanism histone modification directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary the arginine demethylase JMJD6 promotes the demethylation of HNRNPA2B1 at Arg226 and activates its translocation to cytoplasm, which further magnifies the expression of CGAS, IFI16, and Stimulator of interferon genes protein (STING1)
In-vitro Model
 RAW 264.7 Mouse leukemia Mus musculus CVCL_0493
HEK293 Normal Homo sapiens CVCL_0045
HEK293T Normal Homo sapiens CVCL_0063
In-vivo Model Hnrnpa2b1fl/fl and Hnrnpa2b1fl/flLyz2-Cre+ mice were infected with 1×108 plaque-forming units (PFU) of HSV-1 viruses intraperitoneally. Serum IFN-beta concentrations were determined by enzyme-linked immunosorbent assay (ELISA) kit. HSV-1 titers were determined by plaque assays using homogenates from brains of infected mice.
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Stimulator of interferon genes protein (STING1) 17 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name ADU-S100 Phase 2 [2]
Synonyms
MIW815; IZJJFUQKKZFVLH-LTKSHMRXSA-N; 1638241-89-0; AKOS027321070; HY-12885
    Click to Show/Hide
MOA Activator
External Link
CID: 135390762
TTD: D0N6VS
 Compound Name ADU- S100 Phase 2 [3]
MOA Agonist
External Link
TTD: DCIX20
 Compound Name MK-1454 Phase 2 [4]
MOA Agonist
External Link
TTD: DQ4OU8
 Compound Name IMSA101 Phase 1/2 [5]
MOA Agonist
External Link
TTD: DC37YW
 Compound Name BMS-986301 Phase 1 [6]
MOA Agonist
External Link
TTD: D2KOX5
 Compound Name MK-2118 Phase 1 [7]
MOA Agonist
External Link
TTD: D4JU8H
 Compound Name XMT-2056 Phase 1 [8]
MOA Agonist
External Link
TTD: D7AT3H
 Compound Name TAK-500 Phase 1 [9]
MOA Agonist
External Link
TTD: D9ICV2
 Compound Name SB 11285 Phase 1 [10]
MOA Agonist
External Link
TTD: DA79HM
 Compound Name E7766 Phase 1 [11]
MOA Agonist
External Link
TTD: DO7D1L
 Compound Name GSK3745417 Phase 1 [12]
MOA Agonist
External Link
TTD: DQ6J0W
 Compound Name A296 Phase 1 [13]
MOA Agonist
External Link
TTD: DTV17S
 Compound Name TAK-676 Phase 1 [14]
MOA Agonist
External Link
TTD: DTYQ45
 Compound Name SNX281 Phase 1 [15]
MOA Inhibitor
External Link
TTD: DUA7N4
 Compound Name SYNB1891 Phase 1 [16]
MOA Agonist
External Link
TTD: DUR0F6
 Compound Name C-178 Investigative [17]
Synonyms
329198-87-0; STING inhibitor C-178; N-(dibenzo[b,d]furan-3-yl)-5-nitrofuran-2-carboxamide; N-dibenzofuran-3-yl-5-nitrofuran-2-carboxamide; Oprea1_355995; Oprea1_671722; 5-Nitro-furan-2-carboxylic acid dibenzofuran-3-ylamide; SCHEMBL21065360; BCP31292; ZINC4838645; s6667; AKOS000544527; MCULE-6315822200; BS-17017; C 178;C178;STING inhibitor C-178; HY-123963; CS-0087693; ST51004028; N-benzo[3,4-b]benzo[d]furan-3-yl(5-nitro(2-furyl))carboxamide
    Click to Show/Hide
MOA Agonist
External Link
CID: 2866412
TTD: D7CI5F
 Compound Name C-176 Investigative [18]
Synonyms
314054-00-7; N-(4-iodophenyl)-5-nitrofuran-2-carboxamide; C-176 STING inhibitor; STING inhibitor C-176; STING Inhibitor 1; Cambridge id 5344639; Oprea1_000586; Oprea1_014551; 5-Nitro-furan-2-carboxylic acid (4-iodo-phenyl)-amide; CHEMBL3593839; SCHEMBL13219564; ZINC830011; BCP30174; EX-A2974; s6575; STK016322; AKOS000670518; MCULE-4963641555; BS-16912; HY-112906; AK00792625; CS-0067918; ST50232559; C176; C 176; AB00081654-01; N-(4-iodophenyl)(5-nitro(2-furyl))carboxamide; SR-01000406953; SR-01000406953-1
    Click to Show/Hide
MOA Agonist
External Link
CID: 1103958
TTD: DP2F6W
References
Ref 1 Nuclear hnRNPA2B1 initiates and amplifies the innate immune response to DNA viruses. Science. 2019 Aug 16;365(6454):eaav0758. doi: 10.1126/science.aav0758. Epub 2019 Jul 18.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 Magnitude of Therapeutic STING Activation Determines CD8(+) T Cell-Mediated Anti-tumor Immunity. Cell Rep. 2018 Dec 11;25(11):3074-3085.e5. doi: 10.1016/j.celrep.2018.11.047.
Ref 4 National Cancer Institute Drug Dictionary (drug name MK1454).
Ref 5 Clinical pipeline report, company report or official report of ImmuneSensor Therapeutics.
Ref 6 Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. J Clin Med. 2020 Oct 16;9(10):3323. doi: 10.3390/jcm9103323.
Ref 7 National Cancer Institute Drug Dictionary (drug name ML2118).
Ref 8 Clinical pipeline report, company report or official report of GlaxoSmithKline
Ref 9 ClinicalTrials.gov (NCT05070247) An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
Ref 10 Clinical pipeline report, company report or official report of F-star Therapeutics.
Ref 11 E7766, a Macrocycle-Bridged Stimulator of Interferon Genes (STING) Agonist with Potent Pan-Genotypic Activity. ChemMedChem. 2021 Jun 7;16(11):1740-1743. doi: 10.1002/cmdc.202100068. Epub 2021 Feb 25.
Ref 12 National Cancer Institute Drug Dictionary (drug name GSK3745417).
Ref 13 Clinical pipeline report, company report or official report of Klus Pharma
Ref 14 National Cancer Institute Drug Dictionary (drug name TAK676).
Ref 15 Clinical pipeline report, company report or official report of Silicon Therapeutics.
Ref 16 Immunotherapy with engineered bacteria by targeting the STING pathway for anti-tumor immunity. Nat Commun. 2020 Jun 1;11(1):2739. doi: 10.1038/s41467-020-16602-0.
Ref 17 Targeting STING with covalent small-molecule inhibitors. Nature. 2018 Jul;559(7713):269-273. doi: 10.1038/s41586-018-0287-8. Epub 2018 Jul 4.
Ref 18 Stimulator of IFN genes mediates neuroinflammatory injury by suppressing AMPK signal in experimental subarachnoid hemorrhage. J Neuroinflammation. 2020 May 25;17(1):165. doi: 10.1186/s12974-020-01830-4.